ArticleBMC biotechnology2026
Anticancer effects of bisabolol oxide A-Loaded Micellar/Liposomal nanoparticles on DU-145 cells with deregulation of miR-34a and miR-181a: in silico and in vitro studies.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bisabolol oxide A, a key bioactive constituent of Matricaria chamomilla, is recognized for its potent anti-inflammatory, antioxidant, and anticancer properties. This study focused on synthesizing bisabolol oxide A-loaded micellar/liposomal nanoparticles (NPs) and rigorously evaluating their anti-proliferative and anti-invasive effects using integrated in vitro and in silico methodologies. Physicochemical characterization of the bisabolol oxide A-loaded NPs was performed using SEM, TEM, TGA-DTG, Zeta potential, DLS analysis, and FT-IR spectroscopy. Furthermore, drug-like properties for bisabolol oxide A, bisabolol oxide B, and 5,8,11-heptadecatriynoic acid methyl ester were predicted using Swiss ADME software. Molecular dynamics simulations were subsequently conducted for these compounds against critical cellular migration proteins: β-catenin and the Epidermal Growth Factor Receptor (EGFR). The anticancer efficacy of the bisabolol oxide A-loaded nanoparticles was assessed through MTT assays, Annexin V/PI staining, wound healing assays, and qRT-PCR. Characterizations confirmed that the nanoparticles possessed optimal characteristics, exhibiting sizes between 35 to 67 nm, high mono-dispersity and thermal stability up to 380°C. In vitro results demonstrated that bisabolol oxide A-loaded micellar/liposomal nanoparticles significantly inhibited DU-145 cell proliferation, yielding IC₅₀ value of 55.44 µg/mL, 46.21 µg/mL, and 43.59 µg/mL after 24, 48, and 72 hours of treatment. Flow-cytometry analysis further confirmed 50.04% reduced migratory capacity and induction of apoptosis. Mechanistically, qRT-PCR analysis revealed a significant 2.31 ± 0.16-fold upregulation of the tumor-suppressive miR-34a and a 1.72 ± 0.03-fold downregulation of the oncomiR miR-181a in treated cells. These miRNA alterations correlated with the downregulation of migration-associated genes (CTNNB, SMAD3, and EGFR) and the upregulation of apoptosis-related genes (P53 and CASP9), findings substantiated by Western blot analysis. In silico analyses indicated favorable ADMET properties for bisabolol oxide A, bisabolol oxide B, and 5,8,11-heptadecatriyneoic acid methyl ester. Molecular docking simulations revealed strong binding affinities of these compounds for β-catenin and EGFR, which are key proteins in cellular migration pathways. Our findings strongly suggest that bisabolol oxide A functions as an anti-migration and pro-apoptotic agent by effectively modulating the expression of specific miRNAs and their transcriptional targets, complemented by potent inhibitory interactions with critical protein targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.